Study identifier:BY9010/M1-417
ClinicalTrials.gov identifier:NCT00305487
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Efficacy of Ciclesonide (200mcg and 100mcg, once daily) Applied as a Nasal Spray for Two Weeks in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 6 to 11 Years of Age
Hay Fever
Phase 3
No
Ciclesonide nasal spray
All
660
Interventional
6 Years - 11 Years
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
The aim of the study is to determine the efficacy and safety of ciclesonide nasal spray in children with seasonal allergic rhinitis. Ciclesonide will be administered intranasally at two dose levels once daily. The study consists of a baseline period (1 to 3 weeks) and a treatment period (2 weeks).
Location
Location
Rochester, NY, NY, United States, 14618
Location
Charleston, SC, SC, United States, 29407
Location
Woodstock, GA, GA, United States, 30188
Location
Louisville, KY, KY, United States, 40215
Location
Cincinnati, OH, OH, United States, 45231
Location
Lincoln, NE, NE, United States, 68505
Location
Lakewood, CO, CO, United States, 80401
Location
Medford, OR, OR, United States, 97504
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.